ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

13.04 -0.81 (-5.85%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about EyePoint, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: EyePoint Pharmaceuticals Q2 Earnings ↗

August 03, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Preview For EyePoint Pharmaceuticals ↗

August 02, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

EyePoint Pharma Posts 12-Month Safety, Efficacy Data From Early-Stage Wet AMD Trial ↗

July 15, 2022

Via Benzinga

Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock ↗

July 07, 2022

Via Benzinga

Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday ↗

July 18, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 15, 2022

Via Benzinga

EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss ↗

May 04, 2022

Via Benzinga

EyePoint Announces Positive Safety and Efficacy Data From Initial-Stage Wet AMD Study ↗

July 15, 2022

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced 12-month data readout from the Phase 1 DAVIO clinical trial evaluating EYP-1901, targeting wet age-related macular degeneration (wet AMD) as a...

Via Benzinga

7 Wildly Oversold Nasdaq Stocks to Buy Now ↗

July 12, 2022

For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗

July 07, 2022

Upgrades

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Recap: EyePoint Pharmaceuticals Q1 Earnings ↗

May 04, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

EyePoint Pharmaceuticals Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 28, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing ↗

March 09, 2022

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 03, 2022

Gainers Tonix Pharmaceuticals (NASDAQ:TNXP) stock rose 49.1% to $0.28 during Thursday's regular session. As of 12:31 EST, Tonix Pharmaceuticals's stock is trading...

Via Benzinga

Recap: EyePoint Pharmaceuticals Q4 Earnings ↗

March 03, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

Earnings Preview: EyePoint Pharmaceuticals ↗

March 02, 2022

EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement....

Via Benzinga

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

Why EyePoint Pharmaceuticals Shot 31% Higher Today ↗

November 17, 2021

The eyecare specialist has good momentum behind it as it prices a new round of capital raising.

Via The Motley Fool

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

61 Biggest Movers From Yesterday ↗

November 18, 2021

Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share. Braze, Inc. (NASDAQ: BRZE) jumped...

Via Benzinga

Topics Initial Public Offering

Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher ↗

November 17, 2021

Toward the end of trading Wednesday, the Dow traded down 0.58% to 35,930.89 while the NASDAQ fell 0.27% to 15,930.79. The S&P also fell, dropping 0.23% to 4,690.24. The U.S....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 17, 2021

Gainers EyePoint Pharmaceuticals (NASDAQ:EYP...

Via Benzinga

Mid-Day Market Update: StoneCo Drops After Q3 Earnings; EyePoint Pharmaceuticals Shares Surge ↗

November 17, 2021

Midway through trading Wednesday, the Dow traded down 0.51% to 35,958.22 while the NASDAQ rose 0.03% to 15,977.88. The S&P also fell, dropping 0.13% to 4,694.96. The U.S. has...

Via Benzinga

Topics Stocks

42 Stocks Moving In Wednesday's Mid-Day Session ↗

November 17, 2021

Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed...

Via Benzinga

Topics Initial Public Offering

Mid-Morning Market Update: Markets Down; Lowe's Earnings Beat Estimates ↗

November 17, 2021

Following the market opening Wednesday, the Dow traded down 0.34% to 36,017.63 while the NASDAQ fell 0.19% to 15,944.13. The S&P also fell, dropping 0.23% to 4,690.06. The U.S...

Via Benzinga

Topics Earnings Stocks

EyePoint Pharmaceuticals Raises $100M Via Capital Raise At 5% Discount ↗

November 17, 2021

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has priced an underwritten public offering of 4.03 million at $13.75 per share and pre-funded warrants to purchase up...

Via Benzinga

The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment ↗

November 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.